| Drug General Information |
| Drug ID |
D0C5PA
|
| Former ID |
DCL000983
|
| Drug Name |
Sibenadet
|
| Drug Type |
Small molecular drug
|
| Indication |
Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]
|
Discontinued in Phase 3 |
[1]
|
|---|
| Company |
AstraZeneca
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H14N8O7S
|
| Canonical SMILES |
CC1=C2C3=NC(=C(O3)C)C4=NC(=CO4)C5=NC(=CO5)C6=NC(=CO6)C7<br />=NC(=CO7)C8=NC(=CO8)C9=NC(CS9)C(=N2)O1
|
| InChI |
1S/C26H14N8O7S/c1-9-17-24-30-14(6-39-24)21-28-12(4-37-21)19-27-11(3-35-19)20-29-13(5-36-20)22-31-15(7-38-22)26-32-16(8-42-26)23-33-18(10(2)40-23)25(34-17)41-9/h3-7,16H,8H2,1-2H3
|
| InChIKey |
YVSQVYZBDXIXCC-UHFFFAOYSA-N
|
| CAS Number |
CAS 154189-24-9
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14195, 14911415, 36886849, 50430608, 56204580, 57404430, 103635202, 104630272, 134339417, 134340608, 140261817, 223441450, 235367497, 246298695
|
| Target and Pathway |
| Target(s) |
Beta-2 adrenergic receptor |
Target Info |
Modulator |
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Endocytosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Salivary secretionhsa04015:Rap1 signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Beta2 adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Pathway Interaction Database
|
Arf6 trafficking events
|
|
Arf6 signaling events
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Vitamin D Receptor Pathway
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. Epub 2008 Mar 18. |
|---|
